Table 1 Response rate and prevalence of PRKDC mutations in data cohorts from several clinical cohorts [69]
From: Role of PRKDC in cancer initiation, progression, and treatment
Paper | Cancer | Sample size | Sample with PRKDC mutation | Responder with PRKDC | Response rate (%) |
|---|---|---|---|---|---|
Synder et al. | Melanoma | 64 | 2 (3.1%) | 2 | 100 |
Rizvi et al. | NSCLC | 31 | 3 (9.7%) | 2 | 66.70 |
Van Allen et al. | Melanoma | 110 | 9 (8.2%) | 4 | 55.60 |
Anagnostou et al. | NSCLC | 4 | 1 (25%) | 1 | 100 |
Maio et al. | Renal cell carcinoma | 98 | 2 (2.0%) | 1 | 50 |
Riaz et al. | Melanoma | 65 | 2 (3.1%) | 1 | 50 |